Enjoy complimentary customisation on priority with our Enterprise License!
The bronchitis treatment market share is expected to increase by USD 1.12 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.76%.
This bronchitis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers bronchitis treatment market segmentation by drug class (antibiotics, anti inflammatory drugs, and bronchodilator) and geography (North America, Europe, Asia, and Rest of World (ROW)). The bronchitis treatment market report also offers information on several market vendors, including Akorn Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Bronchitis Treatment Market Size for the Forecast Period and Other Important Statistics
The increasing prevalence of smoking is notably driving the bronchitis treatment market growth, although factors such as the high cost of healthcare may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the bronchitis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Bronchitis Treatment Market Driver
The increasing prevalence of smoking is one of the key drivers supporting the bronchitis treatment market growth. According to CDC, in 2020, around 32.51 million consumers in the US used cigarettes. The prevalence of smoking in Canada was 12%, approximately 3.7 million consumers in 2020. This can be attributed to the increasing adoption of e-cigarettes and other chewable tobacco products in North America. Moreover, the UAE allows smoking in public places such as government facilities, restaurants, pubs and bars, public transport, and indoor offices. In South Africa, there were around 6 million smokers in 2019. Public smoking in South Africa has no stringent regulations. Therefore, the prevalence of smoking is much higher in the country. Thus, the increasing prevalence of smoking leads to increased cases of chronic bronchitis. Such factors will positively impact the growth of the global bronchitis treatment market during the forecast period.
Key Bronchitis Treatment Market Trend
Increased healthcare spending worldwide is another factor supporting the bronchitis treatment market growth. The governments of developed nations, such as the US, Germany, France, and Sweden, have increased their healthcare expenditure in recent years. According to the WHO, the global spending on healthcare continually increased between 2000 and 2018 and reached $8.3 trillion or 10% of global GDP. For instance, in 2020, the US spent 19.7% of its GDP on healthcare expenditure. Other European nations such as Germany, France, Sweden, and Austria spent 11.43%, 11.26%, 10.90%, and 10.33%, respectively, of their GDP on healthcare expenditure. The expenditure on prescription drugs and over-the-counter medicines has increased in recent years. Thus, increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will drive the growth of the global bronchitis treatment market during the forecast period.
Key Bronchitis Treatment Market Challenge
The high cost of healthcare is one of the factors hindering the bronchitis treatment market growth. For instance, in 2019, the per capita healthcare expenditure was $7,138 in Switzerland, $6,748 in Norway, and $6,731 in Germany. The high cost of healthcare in these developed countries prevents patients from opting for treatment options for bronchitis. Additionally, in developing countries such as India, China, Brazil, Argentina, and others, due to lack of resources and low per capita income, patients cannot use drugs to treat bronchitis. The absence of proper healthcare infrastructure and less amount government aids received in the form of medical expense reimbursement further pose a challenge for the patients in these countries. Thus, the global per capita healthcare cost is expected to increase during the forecast period. Such factors will negatively impact the growth of the global bronchitis treatment market during the forecast period.
This bronchitis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global bronchitis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the bronchitis treatment market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the bronchitis treatment market encompasses successful business strategies deployed by the key vendors. The bronchitis treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The bronchitis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the bronchitis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for bronchitis treatment market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The advanced healthcare infrastructure in the region will facilitate the bronchitis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the COVID-19 pandemic negatively impacted the regional bronchitis treatment market. However, in H2 2020, the number of COVID-19 cases decreased with the introduction of vaccines in the region. This has led to the resumption of supply chain activities by regional vendors, which has resulted in the availability of various medications for the treatment of bronchitis. Such factors will contribute to the growth of the bronchitis treatment market during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The bronchitis treatment market share growth by the antibiotics segment will be significant during the forecast period. For example, Levofloxacin is an antibiotic that is used to kill the bacteria that cause infections and lead to conditions such as bronchitis. Vendors such as Teva Pharmaceutical Industries Ltd. offer Levofloxacin 500 mg film-coated tablets to treat infections of the lungs in patients with long-term breathing problems or pneumonia. Thus, the availability of a wide range of antibiotic treatment options for treating bronchitis will drive the growth of the market segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the bronchitis treatment market size and actionable market insights on post COVID-19 impact on each segment.
Antibiotics market - The market share is expected to increase by USD 4.44 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 3.03%.
Lung Cancer Therapeutics market - The market share has the potential to grow by USD 6.79 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.47%.
Bronchitis Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.76% |
Market growth 2022-2026 |
$ 1.12 billion |
Market structure |
Fragmented |
YoY growth (%) |
2.96 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key consumer countries |
US, Canada, Australia, New Zealand, and Germany |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Akorn Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Drug Class
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.